Page 1 of 8, showing 50 records out of 368 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. |
Prostate Cancer |
2011 |
|
4770. Labrie, F. (2011) Blockade of all sources of androgens is key to optimal treatment at all stages of prostate cancer: Observations made in the 1980's are the basis of current progress in new drug development. Prostate Cancer Communication – Choices, 27: 3-10. |
Prostate Cancer |
2011 |
|
4753. Labrie, F. (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nature Reviews. 8: 73-80 |
Prostate Cancer |
2011 |
|
4763. Labrie, F. (2011) Editorial: The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab. 6:313-316. |
Prostate Cancer |
2011 |
|
4750. Labrie, F. (2010) Editorial Comment: Kaliks RA et al. Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer. International Braz J Urol. 36: 306-307 |
Prostate Cancer |
2010 |
|
4735. Labrie, F. (2010) Hormonal therapy of prostate cancer. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff De, eds. Pathological Situations and Diseases, Progress in Brain Research. Elsevier. Chapter 14, Vol. 182 321-341. |
Prostate Cancer |
2010 |
|
4723. Samson, M., Labrie, F., Luu-The, V. (2010) Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Clin Invest. 1: 67-72. |
Prostate Cancer |
2010 |
|
4708. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 |
Prostate Cancer |
2010 |
|
4758. Yamana, K., Labrie, F., Luu-The, V (2010) Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride, Horm Mol Biol Clin Invest. 2:293-299. |
Prostate Cancer |
2010 |
|
1. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. |
Prostate Cancer |
2009 |
|
4707. Lévesque, M.H., El-Alfy, M., Cusan, L., Labrie, F. (2009) Androgen receptor as a potential sign of prostate cancer metastasis, The Prostate, 69: 1704-1711. |
Prostate Cancer |
2009 |
|
4692. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. |
Prostate Cancer |
2009 |
|
4699. Ma, C., Yoshioka, M., Boivin, A., Gan, L, Takase, Y, Labrie, F., St-Amand, J. (2009) Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. The Prostate, 69: 293-316 |
Prostate Cancer |
2009 |
|
4683. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. |
Prostate Cancer |
2009 |
|
4694. Labrie, F. (2008) Comment to: Prostate specific antigen (PSA)-based screening. Int J Urol, 15: 757-762. |
Prostate Cancer |
2008 |
|
2. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. |
Prostate Cancer |
2008 |
|
725. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. |
Prostate Cancer |
2008 |
|
3. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. |
Prostate Cancer |
2008 |
|
4687. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. |
Prostate Cancer |
2008 |
|
4. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 241-254. |
Prostate Cancer |
2008 |
|
5. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Prostate Cancer |
2007 |
|
6. Cantin, L., Faucher, F., Couture, J.F., de Jésus, K.P., Legrand, P., Ciobanu, L., Fréchette, Y., Labrecque, R., Singh, S.M., Labrie, F., Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem, 282: 30910-9. |
Prostate Cancer |
2007 |
|
7. Labrie, F. (2007) Multiple intracrine hormonal targets in the prostate: oportunities and challenges. BJU Int, 100: 48-51. |
Prostate Cancer |
2007 |
|
8. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. |
Prostate Cancer |
2007 |
|
9. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha, 17beta-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. |
Prostate Cancer |
2007 |
|
10. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. |
Prostate Cancer |
2007 |
|
11. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. |
Prostate Cancer |
2007 |
|
12. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. |
Prostate Cancer |
2007 |
|
13. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. |
Prostate Cancer |
2007 |
|
14. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. |
Prostate Cancer |
2007 |
|
15. Candas, B., Labrie, F., Gomez, J.L., Cusan, L., Chevrette, E., Levesque, J., Brousseau, G. (2006) Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol, 175: 510-517. |
Prostate Cancer |
2006 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
Prostate Cancer |
2006 |
|
17. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. |
Prostate Cancer |
2006 |
|
18. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. |
Prostate Cancer |
2006 |
|
19. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. |
Prostate Cancer |
2005 |
|
20. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. |
Prostate Cancer |
2005 |
|
21. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
Prostate Cancer |
2004 |
|
22. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
Prostate Cancer |
2004 |
|
23. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
Prostate Cancer |
2004 |
|
24. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. |
Prostate Cancer |
2004 |
|
25. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. |
Prostate Cancer |
2004 |
|
26. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. |
Prostate Cancer |
2004 |
|
27. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. |
Prostate Cancer |
2004 |
|
28. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17beta-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
Prostate Cancer |
2004 |
|
29. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. |
Prostate Cancer |
2004 |
|
30. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
Prostate Cancer |
2003 |
|
31. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. |
Prostate Cancer |
2003 |
|
32. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. |
Prostate Cancer |
2003 |
|
33. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
Prostate Cancer |
2002 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Prostate Cancer |
2002 |